People | May 17, 2024
Takeda appoints Annapurna Das as the General Manager, India Operations
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Investing in Malaysia's largest clinic operator to expand the healthcare business
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Subscribe To Our Newsletter & Stay Updated
